Imexpharm (STC:IMP) E10: ₫0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:IMP Imexpharm Corp STC:IMP
88 GF Score
Price ₫36,700.00
GF Value ₫46,395.26
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Imexpharm E10?

Imexpharm STC:IMP 88 E10 is ₫0.00 as of Jun. 2026. GuruFocus rates STC:IMP with a GF Score™ of 88/100 and a GF Value™ of ₫46,395.26 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Imexpharm's adjusted earnings per share data for the three months ended in Jun. 2026 was ₫0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₫0.00 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-10), Imexpharm's current stock price is ₫36700.00. Imexpharm's E10 for the quarter that ended in Jun. 2026 was ₫0.00. Imexpharm's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Imexpharm was 41.73. The lowest was 18.74. And the median was 27.46.


Imexpharm  (STC:IMP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Imexpharm was 41.73. The lowest was 18.74. And the median was 27.46.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Imexpharm E10 Related Terms


Imexpharm E10 Historical Data

* Premium members only.

The historical data trend for Imexpharm's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm E10 Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 980.06 1,052.71 1,174.24 0.00 0.00

Imexpharm Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,306.63 0.00 1,366.43 0.00

STC:IMP vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Imexpharm's Shiller PE Ratio falls into.


STC:IMP
88GF Score
Imexpharm Corp STC:IMP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imexpharm's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Imexpharm Quarterly Data

per share eps CPI Adj_EPS
201609 199.910 241.428 276.523
201612 212.173 241.432 293.481
201703 206.469 243.801 282.816
201706 198.085 244.955 270.053
201709 170.209 246.819 230.297
201712 161.354 246.524 218.577
201803 221.042 249.554 295.797
201806 181.359 251.989 240.349
201809 234.633 252.439 310.396
201812 150.927 251.233 200.620
201903 212.187 254.202 278.756
201906 190.542 256.143 248.423
201909 320.346 256.759 416.656
201912 303.495 256.974 394.409
202003 244.156 258.115 315.892
202006 280.519 257.797 363.386
202009 273.160 260.280 350.478
202012 402.133 260.474 515.572
202103 266.234 264.877 335.663
202106 281.818 271.696 346.393
202109 178.788 274.310 217.661
202112 399.591 278.802 478.634
202203 300.433 287.504 348.970
202206 257.143 296.311 289.808
202209 307.792 296.808 346.311
202212 187.263 296.797 210.706
202303 429.545 301.836 475.250
202306 479.545 305.109 524.878
202309 420.000 307.789 455.701
202312 436.000 306.746 474.670
202403 373.000 312.332 398.820
202406 0.000 314.175 0.000
202409 404.000 315.301 427.898
202412 0.000 315.605 0.000
202503 431.000 319.799 450.074
202506 0.000 322.561 0.000
202509 429.000 324.800 441.088
202512 0.000 324.054 0.000
202603 474.000 330.213 479.367
202606 0.000 333.952 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₫0.00 mean?
Imexpharm (STC:IMP) has a E10 of ₫0.00 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Imexpharm and its competitors.
Is Imexpharm's E10 too high?
Imexpharm's current E10 is ₫0.00. Overall, Imexpharm has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's E10 compare to ZTS?
Imexpharm's E10 of ₫0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Imexpharm and its competitors. Imexpharm's current E10 is ₫0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫46,395.26, compared to a current price of ₫36,700.00 — trading 20.9% below its estimated fair value. The current E10 is ₫0.00. Imexpharm's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current E10 is ₫0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫36,700.00 is trading 20.9% below its estimated GF Value™ of ₫46,395.26. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • E10: ₫0.00
  • GF Value™: ₫46,395.26 vs. price of ₫36,700.00 (20.9% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
88GF Score

Get the complete analysis for STC:IMP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫36,700.00
Price
₫46,395.26
GF Value